scholarly journals The in vitro cytotoxic activity of ethno-pharmacological important plants of Darjeeling district of West Bengal against different human cancer cell lines

Author(s):  
Bipransh K Tiwary ◽  
Sony Bihani ◽  
Anoop Kumar ◽  
Ranadhir Chakraborty ◽  
Runu Ghosh
Toxicon ◽  
2019 ◽  
Vol 158 ◽  
pp. S49
Author(s):  
Toktam M. Kashani ◽  
Amir Salarian ◽  
Hossein Vatanpour ◽  
Farshad Shirazi ◽  
Abbas Zare ◽  
...  

2011 ◽  
Vol 8 (6) ◽  
pp. 1152-1162 ◽  
Author(s):  
Rosa Tundis ◽  
Monica R. Loizzo ◽  
Federica Menichini ◽  
Marco Bonesi ◽  
Carmela Colica ◽  
...  

2017 ◽  
Vol 1 (5) ◽  
pp. 199-202
Author(s):  
Rahamat Unissa ◽  
◽  
Sai Cheruvu ◽  
Mulakalapalli Tejaswi ◽  
Mareda Raghavi ◽  
...  

2012 ◽  
Vol 38 ◽  
pp. 153-159 ◽  
Author(s):  
Marijana Skorić ◽  
Slađana Todorović ◽  
Nevenka Gligorijević ◽  
Radmila Janković ◽  
Suzana Živković ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (13) ◽  
pp. 3923
Author(s):  
Adel A.-H. Abdel-Rahman ◽  
Amira K. F. Shaban ◽  
Ibrahim F. Nassar ◽  
Dina S. EL-Kady ◽  
Nasser S. M. Ismail ◽  
...  

New pyridine, pyrazoloyridine, and furopyridine derivatives substituted with naphthyl and thienyl moieties were designed and synthesized starting from 6-(naphthalen-2-yl)-2-oxo-4-(thiophen-2-yl)-1,2-dihydropyridine-3-carbonitrile (1). The chloro, methoxy, cholroacetoxy, imidazolyl, azide, and arylamino derivatives were prepared to obtain the pyridine-−C2 functionalized derivatives. The derived pyrazolpyridine-N-glycosides were synthesized via heterocyclization of the C2-thioxopyridine derivative followed by glycosylation using glucose and galactose. The furopyridine derivative 14 and the tricyclic pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine 15 were prepared via heterocyclization of the ester derivative followed by a reaction with formamide. The newly synthesized compounds were evaluated for their ability to in vitro inhibit the CDK2 enzyme. In addition, the cytotoxicity of the compounds was tested against four different human cancer cell lines (HCT-116, MCF-7, HepG2, and A549). The CDK2/cyclin A2 enzyme inhibitory results revealed that pyridone 1, 2-chloro-6-(naphthalen-2-yl)-4-(thiophen-2-yl)nicotinonitrile (4), 6-(naphthalen-2-yl)-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-amine (8), S-(3-cyano-6-(naphthaen-2-yl)-4-(thiophen-2-yl)pyridin-2-yl) 2-chloroethanethioate (11), and ethyl 3-amino-6-(naphthalen-2-yl)-4-(thiophen-2-yl)furo[2,3-b]pyridine-2-carboxylate (14) are among the most active inhibitors with IC50 values of 0.57, 0.24, 0.65, 0.50, and 0.93 µM, respectively, compared to roscovitine (IC50 0.394 μM). Most compounds showed significant inhibition on different human cancer cell lines (HCT-116, MCF-7, HepG2, and A549) with IC50 ranges of 31.3–49.0, 19.3–55.5, 22.7–44.8, and 36.8–70.7 μM, respectively compared to doxorubicin (IC50 40.0, 64.8, 24.7 and 58.1 µM, respectively). Furthermore, a molecular docking study suggests that most of the target compounds have a similar binding mode as a reference compound in the active site of the CDK2 enzyme. The structural requirements controlling the CDK2 inhibitory activity were determined through the generation of a statistically significant 2D-QSAR model.


Sign in / Sign up

Export Citation Format

Share Document